The American Diabetes Association (ADA) 77th Scientific Sessions will be held in San Diego, CA from 9–13 June 2017.

Cardiovascular outcomes trials (CVOTs) of diabetes drugs will be a big topic at this year's conference. The highlights are previously unreleased CVOT results from SGLT2 inhibitor Invokana's (JNJ, DSKYF, Mitsubishi, PDLI) CANVAS program, which could help confirm a class benefit on CV death, and first conference details from Tresiba's (NVO) DEVOTE, which while not demonstrating superiority on CV events compared to Lantus (SNY), did show a drop in severe hypoglycemia. Other sessions will have new data from previously released CVOTs, as well as cost effectiveness of such newer therapies and implications for guidelines.

There will also be first release of data or first conference details for a number of other drugs, including: oral GLP-1 agonist TTP273 (VTVT), biosimilar insulins SAR342434 (SNY) and MYL-1501D (Mylan, Biocon), ultra-rapid mealtime insulin LY900014 (LLY), SGLT1/2 inhibitor sotagliflozin (SNY, LXRX) in type 1 diabetes, MetAP2 inhibitor ZGN-1061 (ZFGN), and oxyntomodulin analog LY2944876 (OPK, LLY).

We highlight these and other presentations below. For additional posters that are of possible interest, please see those recommended in the accompanying Excel planner.

Full abstracts will be available on Friday 2 June, but will still be embargoed until presentation.

Drugs Highlighted:

• Cardiovascular Outcomes Trials (CVOTs) of Diabetes Drugs: Invokana (JNJ, DSKYF, Mitsubishi, PDLI), Jardiance (Boehringer, LLY), Tresiba (NVO), semaglutide (NVO), Victoza (NVO)


• Other SGLT2 Inhibitor Presentations: sotagliflozin (SNY, LXRX), ertugliflozin (MRK, PFE)


• Other GLP-1 Agonist Presentations: TTP273 (VTVT), oral semaglutide (NVO, EMIS)


• Insulins: SAR342434 (SNY), MYL-1501D (MYL, Biocon), LY900014 (LLY), BioChaperone Lispro (Adocia), Toujeo (SNY), Tresiba (NVO), Xultophy (NVO), Diamyd (DMYDY)


• PCSK9 Inhibitors: Praluent (REGN, SNY)


• Other Mechanisms: ZGN-1061 (ZFGN), LY2944876 (OPK, LLY), RG7992 (Roche), Bimagrumab (NVS, MorphoSys), TMG- 123 (Teijin)

To download the full conference planner in PDF, click the link at the top of the page. The support material includes a full Excel planner that allows you to select presentations/posters and then automatically create your own printable planner. It also includes potentially notable presentations/posters, primarily clinical, recommended by our analysts.

If you have already selected presentations on the ADA itinerary planner and would like to format them like our Excel planner, please contact askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.